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Abstract
 
A plexus of lymphatic vessels guides interstitial fluid, passenger leukocytes, and tumor cells to-
ward regional lymph nodes. Microvascular endothelial cells (ECs) of lymph channels (LECs)
are difficult to distinguish from those of blood vessels (BECs) because both express a similar set
of markers, such as CD31, CD34, podocalyxin, von Willebrand factor (vWF), etc. Analysis of
the specific properties of LECs was hampered so far by lack of tools to isolate LECs. Recently,
the 38-kD mucoprotein podoplanin was found to be expressed by microvascular LECs but not
BECs in vivo. Here we isolated for the first time podoplanin
 
 
 
 LECs and podoplanin
 
 
 
 BECs
from dermal cell suspensions by multicolor flow cytometry. Both EC types were propagated
and stably expressed VE-cadherin, CD31, and vWF. Molecules selectively displayed by LECs
in vivo, i.e., podoplanin, the hyaluronate receptor LYVE-1, and the vascular endothelial cell
growth factor (VEGF)-C receptor, fms-like tyrosine kinase 4
 
 (
 
Flt-4)/VEGFR-3, were strongly
expressed by expanded LECs, but not BECs. Conversely, BECs but not LECs expressed
VEGF-C. LECs as well as BECs formed junctional contacts with similar molecular composi-
tion and ultrastructural features. Nevertheless, the two EC types assembled in vitro in vascular
tubes in a strictly homotypic fashion. This EC specialization extends to the secretion of biolog-
ically relevant chemotactic factors: LECs, but not BECs, constitutively secrete the CC chemo-
kine receptor (CCR)7 ligand secondary lymphoid tissue chemokine (SLC)/CCL21 at their
basal side, while both subsets, upon activation, release macrophage inflammatory protein
(MIP)-3
 
 
 
/CCL20 apically. These results demonstrate that LECs and BECs constitute stable
and specialized EC lineages equipped with the potential to navigate leukocytes and, perhaps
also, tumor cells into and out of the tissues.
Key words: endothelial cell lineages • podoplanin • endothelial cell tube formation • vascular 
endothelial cell growth factors • chemokines
 
Introduction
 
The microvasculature of the blood and lymphatic systems
form anatomically distinct, nonanastomozing networks (1–
3). However, they constitute a functional continuum, in
which the task of blood vessels is to import fluids, dissolved
proteins, and cells into interstitial spaces, while the lym-
phatics provide the complementary exit route. Presumably,
endothelial cells (ECs)
 
*
 
 of blood vessels (BECs) and of lym-
phatic channels (LECs) are specialized and adapted for dis-
tinct functions. It would be a major achievement, if the dif-
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ferent molecular make-ups of LECs and BECs could be
assembled into a catalog of gene expression and function.
This could provide the basis for the understanding of the
molecular mechanisms of complex processes such as trans-
port of APCs and metastatic spread of tumor cells into re-
gional lymph nodes. To unravel these functional differ-
ences, isolation and culturing of LECs and BECs are
required. While isolated BECs are available from several
tissues, this is not the case for LECs and, therefore, our
present knowledge about the molecular regulation of LEC
function is rudimentary, at best.
In this study we capitalized on our recent observation
that the 38-kD transmembrane mucoprotein podoplanin is
expressed by LECs in various human tissues (4), and serves
as specific, protease-resistant marker for the isolation of
pure LEC and BEC populations. This has opened the pos-
sibility to determine some of the characteristic features of
LECs, to analyze their lineage fidelity and functional reper-
toire, with special reference to the production of factors
that govern leukocyte trafficking in vivo.
 
Materials and Methods
 
Abs.
 
Primary nonconjugated mouse mAbs used were anti–
VE-cadherin (Immunotech), -CD31 (Ancell), -CD44 (Bender
MedSystems), -CD45 (Becton Dickinson), and Pal-E (Harlan
Sera-Lab). FITC-conjugated Abs included anti-CD34 (Becton
Dickinson), sheep anti-von Willebrand factor (vWF; Serotec),
goat anti–mouse F(ab
 
 
 
)
 
2
 
 (Jackson ImmunoResearch Laborato-
ries), and goat anti–rabbit F(ab
 
 
 
)
 
2
 
 (Immunotech). PE- and RPE-
Cy5–conjugated mAbs were anti-CD34 (Becton Dickinson) and
anti-CD45 (Serotec). Biotinylated reagents were anti-CD31 (An-
cell) and 
 
Ulex europeaus
 
 agglutinin I (UEA I; Vector Laboratories).
The binding of biotinylated reagents was revealed by PE-conju-
gated streptavidin (Becton Dickinson). Preimmune goat IgG was
obtained from Sigma-Aldrich. Goat anti–rabbit IgG conjugated
to 10-nm gold particles was purchased from Amersham Pharma-
cia Biotech. Rabbit anti-podoplanin IgG was generated and char-
acterized as described (4), using recombinant human podoplanin
as the antigen. Human podoplanin (sequence data are available
from GenBank/EMBL/DDBJ under accession no. AF390106)
was expressed in 
 
Escherichia coli
 
, and purified by FPLC (reference
4, and unpublished data). Rabbits were initially immunized with
50 mg antigen in CFA, followed by two boosts, and antisera were
affinity-purified on nitrocellulose immobilized podoplanin, as de-
scribed (4). Rabbit anti-caveolin was obtained from Becton
Dickinson.
 
Dermal Cell Suspensions.
 
Dermatomed 0.8-mm split-thick-
ness skin was obtained from adult healthy individuals undergoing
elective surgery (breast reduction and abdominoplasty). Dermal
sheets were prepared by incubation of split-thickness skin with
dispase (50 U/ml; Collaborative Medical Products) for 30 min at
37
 
 
 
C, and subsequent removal of the epidermis. Dermal cells
were released from the tissue by scraping. Cells were pelleted, re-
suspended in EC growth medium MV (PromoCell), and either
seeded on fibronectin (10 
 
 
 
g/ml; Life Technologies)-coated
dishes for in vitro expansion, or subjected to immunostaining as
described below.
 
Immunoisolation of EC Subsets from Dermal Cell Suspensions (Ap-
proach A).
 
The procedures below are for the isolation of
podoplanin
 
 
 
 and podoplanin
 
 
 
 microvascular ECs from freshly
 
prepared dermal cell suspensions (approach A)
 
. 
 
Dermal cells were
incubated for 7 min at 37
 
 
 
C in trypsin/EDTA (Life Technolo-
gies). Cell pellets were resuspended in ice-cold PBS/2 mM
EDTA/0.5% BSA (Sigma-Aldrich), and the resulting cell suspen-
sion was filtered through a sterile sieve with 200 
 
 
 
m mesh-size,
to remove fibers and cell aggregates. Cells were adjusted to 10
 
7
 
cells/ml in EC growth medium MV, supplemented with 10 
 
 
 
g/
ml normal goat IgG, and exposed simultaneously to rabbit anti-
podoplanin serum (final concentration: 1:100), anti–CD34-PE
and anti–CD45-RPE-Cy5 (2 
 
 
 
g/ml each), or to appropriate
control Abs for 45 min on ice. After two washes, the binding of
rabbit Abs was revealed by incubation with goat anti–mouse
F(ab
 
 
 
)
 
2
 
 FITC (10 
 
 
 
g/ml for 30 min). The staining procedure did
not interfere with cell viability, as determined by trypan blue ex-
clusion (data not shown). Cells were washed, resuspended in cold
PBS/2 mM EDTA/0.5% BSA, and subjected to flow cytometry
analysis. Podoplanin
 
 
 
CD34
 
 
 
CD45
 
 
 
 and podoplanin
 
 
 
CD34
 
 
 
CD45
 
 
 
 EC subsets were sorted on a FACStar
 
PLUS™
 
 flow cytome-
ter (Becton Dickinson). The purity of the sorted cell fractions was
analyzed on a FACScan™ (Becton Dickinson) and always ex-
ceeded 98%. 0.5 
 
 
 
 10
 
6
 
 sorted cells/ml were cultured on fi-
bronectin (10 
 
 
 
g/ml)-coated 96-well flat bottom plates (Becton
Dickinson) in EC growth medium MV.
 
Isolation of Subsets from Bulk Cultures of Dermal ECs (Ap-
proach B).
 
Freshly isolated dermal cell suspensions were cultured
in EC growth medium MV until confluent monolayers were
formed. Loosely attached cells were discarded and adherent cells
harvested by trypsinization as described above. 10
 
8
 
 streptavidin-
conjugated paramagnetic beads (Dynal) were coated with 10 
 
 
 
g
biotinylated UEA I. Dermal cells (10
 
7
 
/ml) were incubated with
UEA I–coated beads (bead/cell ratio, 1:4), and ECs attached to
the beads were isolated using a magnet. UEA I
 
 
 
 ECs were
passaged twice, harvested by trypsinization, and exposed simulta-
neously to anti-podoplanin (1:100), anti-CD31–biotin, and anti-
CD45–RPE-Cy5 Abs (2 
 
 
 
g/ml each) followed by streptavidin-
PE and goat anti–mouse F(ab
 
 
 
)
 
2
 
 FITC. ECs were sorted into
podoplanin
 
 
 
CD31
 
 
 
CD45
 
 
 
 and podoplanin
 
 
 
CD31
 
 
 
CD45
 
 
 
 sub-
sets on a FACStar
 
PLUS™
 
.
 
Flow Cytometry Analysis of Blood Vessel and Lymphatic ECs.
 
Plastic-adherent EC subsets were washed twice in ice-cold PBS/
2 mM EDTA/0.5% BSA and then detached from the plates by
gentle pipetting. Cells obtained were incubated with the indi-
cated primary Abs or with appropriate control Abs for 60 min on
ice. Primary Abs were detected by incubation with goat anti–
mouse F(ab
 
 
 
)
 
2
 
 FITC or goat anti–rabbit F(ab
 
 
 
)
 
2
 
 FITC (2 
 
 
 
g/ml
each). To reveal cytoplasmic vWF expression, cells were fixed
and permeabilized before the immunostaining procedure, using a
kit according to the manufacturer’s instructions (Fix&Perm; An
der Grub). Cellular fluorescence was analyzed on a FACScan™
flow cytometer.
 
Double Immunofluorescence of Tissue Sections and Cultured ECs.
 
5-
 
 
 
m cryosections were cut from skin specimens of healthy hu-
man donors, mounted onto glass slides, air-dried, and rehydrated
in HBSS. ECs were cultured on fibronectin-coated LabTek
chamber glass slides (Nunc). Cells were fixed in 4% paraformal-
dehyde (PFA)/PBS for 20 min. Slide-bound ECs or skin sections
were incubated for 30 min in blocking solution (5 mM CaCl
 
2
 
,
1% BSA, and 10 
 
 
 
g/ml goat IgG in HBSS) before their simulta-
neous exposure to rabbit anti-podoplanin and the indicated
mAbs overnight. Binding of the primary polyclonal and mono-
clonal Abs was revealed by subsequent incubation with goat
anti–mouse TRITC and goat anti–rabbit FITC (5 
 
 
 
g/ml each).
Samples were mounted in Vectorshield medium (Vector Labora- 
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tories) and were analyzed by laser scanning microscopy (LSM
410; ZEISS).
 
Immunoelectron Microscopy.
 
UEA I
 
 
 
 ECs were isolated as de-
scribed above and expanded through five culture passages. ECs
were harvested, seeded onto fibronectin-coated glass coverslips,
and cultured for the indicated time periods. Then, coverslip-
bound ECs were fixed in 4% PFA/PBS for 6 h at 20
 
 
 
C, and pro-
cessed for preembedding anti-podoplanin immunogold labeling,
as described (4). Ultra-thin sections were examined under a
JEOL 100 CX electron microscope (JEOL).
 
Immunoblotting.
 
ECs were grown to 80% confluence, lysed in
reducing SDS sample buffer, and proteins were electrophoresed
by 5–15% gradient or 6% straight SDS-PAGE and transferred
onto nitrocellulose membranes (Bio-Rad Laboratories). Mem-
branes were cut and strips were incubated with the following
Abs: rabbit anti-podoplanin (final dilution 1:1,000), rabbit fms-
like tyrosine kinase 4
 
 (
 
Flt-4) (C-terminus-reactive), -KDR, -Flt-1,
-Tie-1, -Tie-2 (0.5 
 
 
 
g/ml each; Santa Cruz Laboratories, Inc.),
or mouse anti-CD31 (0.5 
 
 
 
g/ml). Strips were washed, and bind-
ing of primary Abs was revealed as described previously (5).
 
Northern Blotting.
 
Total RNA was extracted using Tri-
Reagent (Molecular Research Center) according to the manufac-
turer’s instructions. 20 
 
 
 
g of RNA were separated on 1% formal-
dehyde-agarose gels and transferred onto Zeta Probe nylon
membranes (Bio-Rad Laboratories), and hybridized to the fol-
lowing 
 
32
 
P-labeled cDNA fragments: podoplanin (nucleotides
[nt] 136–653), LYVE-1 (nt 91–1054), Flt-4 (nt 554–1340),
CD31 (nt 605–1397), vascular endothelial cell growth factor
(VEGF)-C (nt 353–849), and 
 
 
 
-actin (CLONTECH Laborato-
ries, Inc.). Hybridization was performed at 65
 
 
 
C for 18 h. Then,
membranes were washed twice in 5% SDS/20 mM Na
 
2
 
HPO
 
4
 
,
pH 7.2, at 65
 
 
 
C for 30 min followed by two washes in 1% SDS/
20 mM Na
 
2
 
HPO
 
4
 
, pH 7.2, at 60
 
 
 
C for 10 min, and exposed for
1 to 3 d to X-ray films.
 
Tube-forming Assay.
 
Plastic-adherent ECs were labeled with
5(and 6)-([{4 chloromethyl}benzoyl] amino)tetramethylrho-
damino (CMTMR) or with 5-chloromethylfluorescein diacetate
(CMFDA) fluorescent cell trackers (100 nM; both from Molec-
ular Probes) in HBSS for 15 min at 37
 
 
 
C. Free label was re-
moved, cells were cultured for 12 h in EC growth medium, and
detached from the plate by trypsin/EDTA. 24-well culture
dishes were coated with 0.5 ml Matrigel (both from Becton
Dickinson) per well on ice and gels were allowed to solidify for
60 min at 20
 
 
 
C. 2.5 
 
 
 
 10
 
5
 
 CMTMR- or CMFDA-labeled ECs
were seeded into individual Matrigel-coated wells and incu-
bated for 24 h. Finally, cells were fixed in 4% PFA/HBSS for 30
min and samples were analyzed by confocal laser scanning mi-
croscopy. In some experiments equal numbers of prelabeled
BECs and LECs were mixed 1:1, and then subjected to the
tube-forming assay.
 
Cytokine Stimulation of Lymphatic and Blood Vessel ECs.
 
ECs
were grown to confluence in EC growth medium MV in 75-cm
 
2
 
culture flasks (Becton Dickinson), or onto 0.4-
 
 
 
m poresize Trans-
wells™ inserted into individual wells of 24-well plates (Costar).
Then, full medium was replaced by EGF- and hydrocortisone-
deficient EC growth medium MV, and cells were cultured for
24 h to confluence. Plastic-adherent and Transwell™-bound ECs
were washed twice and cells were cultured in the presence or ab-
sence of TNF
 
 
 
 (100 U/ml) or IL-1
 
 
 
 (0.1 ng/ml; both from
R&D Systems). After 24 h, culture fluid from supernatant (from
the upper and lower compartment in Transwell™ experiments)
were harvested, and CCL19, CCL21, and CCL20 were measured
by ELISA (vide infra).
 
Chemokine ELISA.
 
96-well ELISA plates (MaxiSorp™;
Nunc) were coated with affinity-purified rabbit anti-CCL19,
anti-CCL20, or anti-CCL21 Abs (0.2 
 
 
 
g/well each; all from
PeproTech). 200 
 
 
 
l of EC-conditioned medium, fresh EC cul-
ture medium, or serial dilutions of recombinant CCL19, CCL20,
or CCL21 (all from R&D Systems) were incubated at 4
 
 
 
C over-
night. Plates were rinsed, and 0.2 
 
 
 
g of affinity-purified goat
anti-CCL19, anti-CCL20, or anti-CCL21 (all from R&D Sys-
tems) were added to individual wells. After 45 min, plates were
washed and incubated with biotin-conjugated rabbit anti–goat
IgG, followed by incubation with alkaline phosphatase–conju-
gated streptavidin for 30 min (both from Sigma-Aldrich). CSPD
alkaline phosphatase (Boehringer) was used as substrate, and sig-
nal intensities were measured on a luminometer (Berthold). All
ELISA systems used were chemokine specific, and in control ex-
periments 11 additional nontarget chemokines (CCL2, CCL3,
CCL5, CCL7, CCL8, CCL13, CCL17, CCL22, CXCL12,
CXCL13, CX3CL1; all from R&D Systems) failed to produce
signals.
 
Results
 
Identification and Isolation of Dermal Lymphatic and Blood
Vessel ECs.
 
Dermal LECs, but not BECs, express
podoplanin, while both EC subsets display CD34 (4; Fig.
1, A–C), and are consistently devoid of CD45 (6, 7). The
only other dermal cell type known to display anti-CD34
reactivity is the fibrocyte that, however, expresses CD45
(8). Dermal cells were isolated by enzymatic digestion of
dermal sheets, and labeled simultaneously with anti-
Figure 1. Identification of dermal BECs and LECs in cryostat sections
of human skin (A–C), and isolation by FACS® (D–F). (A–C) Immunoflu-
orescence double-labeling using Abs to podoplanin (TRITC, red), and
CD34 (FITC, green). FITC and TRITC fluorescence images are shown
in B and C. Panel A illustrates the double exposure with LECs (yellow-
red) expressing both podoplanin and CD34. Microvascular tubes shown
are ascending from the superficial vascular plexus (original magnification:
 400). (D–F) Isolation of BECs and LECs from dermal cell suspensions
(approach A) prepared by enzymatic digestion. Cells were triple-labeled
with anti-CD45 Cy5, anti-CD34-PE, and anti-podoplanin. CD45  cells
were gated electronically, and podoplanin /CD34high (green, BECs) and
podoplanin /CD34low ECs (red, LECs) were identified (D) and isolated
(E and F) by FACS®. The purity of the two sorted EC subsets was  98%.800 Phenotype and Function of Lymphatic and Blood Microvascular Endothelial Cells
podoplanin, -CD34, and -CD45 Abs (Materials and Meth-
ods, approach A). After exclusion of CD45  cells, two EC
populations with nonoverlapping immunophenotypes, i.e.,
podoplanin /CD34low   LECs (red dots; Fig. 1 D), and
podoplanin /CD34high    BECs (green dots; Fig. 1 D)
were clearly separated by flow cytometry. The minor
podoplanin /CD34 /CD45  cell population was presum-
ably derived from large lymphatic vessels. By flow sorting,
we obtained microvascular LECs and BECs at a purity of
 98% (Fig. 1, E and F), without any intercalated culture
step. As average yield from 15 independent experiments,
CD34  ECs accounted for 5–10% of total dermal cells, and
70% therefrom were LECs and 30% BECs.
Separated microvascular EC populations were cultured
in standard EGF-, hydrocortisone-, and bovine hypotha-
lamic extract–conditioned EC growth medium (EC
growth medium MV™). They formed cell clusters in the
first days and, then, progressively confluent EC monolayers
by day 7 to 10. Monolayers of LECs and BECs were indis-
tinguishable by phase contrast microscopy (Fig. 2, A and
B). Both EC populations were propagated for at least seven
passages without altering their morphology.
Dermal Microvascular EC Bulk Cultures Contain Two Dis-
tinct EC Types that Differentially Express Podoplanin. As the
number of LECs isolated directly from dermal cell suspen-
sions was relatively low, we increased their yield by ex-
panding freshly prepared dermal cells in EC growth me-
dium, followed by enrichment of ECs by use of UEA
I–conjugated magnetic beads, and two further passages of
UEA I  ECs (Materials and Methods, approach B). Bulk
cultured microvascular ECs, while of homogeneous ap-
pearance by light microscopy, contained two immunophe-
notypically distinct cell populations (Fig. 2 C). As shown in
Fig. 2 C, islands of podoplanin  LECs are surrounded by
podoplanin  BECs. For the FACS® sorting of preexpanded
EC subsets, anti-CD31 instead of anti-CD34 mAbs were
added to the immunolabeling mix as ECs downregulate
CD34 during in vitro culture (reference 9, and data not
shown). This amplification and cell sorting strategy yielded
10 times more ECs than direct isolation without interven-
ing cell expansion. EC subsets isolated by approach B were
identical to those generated by approach A; they also
formed cell clusters and monolayers, and could be propa-
gated for at least seven culture cycles.
Isolated and Cultured Lymphatic and Blood Vessel ECs Sta-
bly Express Cell Type–specific Markers. Expression of EC
subset-defining and pan-EC antigens by LECs and BECs
was determined at various passages (passage 1–7) by flow
cytometry (EC subsets generated by approach A and B)
as well as by Northern and/or Western blotting (EC
Figure 2. BECs and LECs cannot be distinguished by conventional light microscopy when grown separate (A, BECs; B, LECs). (C) In mixed cultures,
immunolabeling with anti-podoplanin (TRITC, red) and anti-vWF (FITC, green) reveal multicellular islands of podoplanin /vWF  LECs surrounded
by podoplanin /vWF  BECs. BECs express more vWF than LECs (see also Fig. 3 A). Original magnification in A and B:  300; C: 250. To confirm
their phenotypic stability, cultured LECs and BECs were harvested, labeled with anti-podoplanin IgG, and analyzed by FACS® (insets in A–C; dotted
line denotes the cut-off for podoplanin positivity). Cultured BECs (A) were homogeneously podoplanin-negative, cultured LECs (B) exclusively
podoplanin-positive, while the mixed EC population (C) contained both qualities.801 Kriehuber et al.
subsets generated by approach B). Among the subset-
restricted markers, LECs retained expression of 38 kD
podoplanin, while BECs were consistently devoid of this
moiety, irrespective of the purification strategy used
(Fig. 3, A and C). Two species of podoplanin mRNA
were observed by Northern blotting that presumably
originate from alternative splicing (Fig. 3 B). Also the
hyaluronate receptor LYVE-1 was selectively expressed
by LECs, but not by BECs, similar to the in vivo situa-
tion (10; Fig. 3 B). Conversely, BECs, but not LECs,
expressed the hyaluronate receptor CD44 and the PAL-
E–reactive antigen (Fig. 3 A). PAL-E reactivity, how-
ever, was progressively downregulated after the second
culture cycle. Of the characteristic pan-EC markers,
both EC types maintained expression of CD31, VE-cad-
herin, and vWF (Fig. 2 C, and Fig. 3, A and B) and con-
tained caveolae and Weibel-Palade (WP) bodies (Fig. 4).
WP bodies were encountered more frequently and the
WP body–associated antigen vWF was expressed at 10
times higher levels in cultured BECs than in LECs (Fig.
3 A). Expectedly, neither BECs nor LECs expressed
CD45, smooth muscle actin, cytokeratins, and neurofila-
ments (data not shown).
Differential Expression of Vascular Growth Factors and Their
Receptors by Lymphatic and Blood Vessel ECs. LECs and, to
a much lesser extent, BECs express the VEGF-C/D recep-
tor Flt-4 in vivo (1, 11–14). This expression profile is also
recapitulated by in vitro propagated LECs and BECs. Cul-
tured LECs, rather than BECs, pronouncedly express Flt-4
both at the mRNA and the protein level (Fig. 3, B and D).
Anti–Flt-4 Ab-reactive 140-, 175-, and 195-kD bands pre-
sumably are differentially processed isoforms of the VEGF-
C/D receptor (15), and were predominantly expressed by
LECs (Fig. 3 C). The  120–125-kD moieties that are ex-
pressed by LECs and in high levels by BECs (Fig. 3 D),
correspond to proteolytic COOH-terminal fragments of
Flt-4 (15). Contrary to the expression pattern of Flt-4, its
ligand, VEGF-C, was produced by BECs, but not by LECs
(Fig. 3 B). Two other VEGF receptors, Flt-1/VEGFR-1,
and KDR/VEGFR-2, and the angiopoietin receptors Tie
Figure 3. Isolated LECs and BECs maintain their
lineage-restricted antigen expression profile during in
vitro expansion. (A) FACS® analysis. Primary LECs
and BECs were isolated by FACS®, and propagated
in vitro. Single cell suspensions of BECs or LECs
were exposed to anti-CD31, anti–VE-cadherin/cad-
herin-5, anti-CD44, anti–PAL-E or to isotype-
matched control mAbs and to rabbit anti-vWF, anti-
podoplanin, or to preimmune rabbit serum. Dead
cells were excluded by propidium iodide counter-
staining and appropriate gate settings. For the analysis
of vWF expression, ECs were fixed and permeabi-
lized before immunostaining. Cells were used after
the sixth passage (expansion factor:  2,500) with the
exception of cells that were stained with PAL-E
which were harvested after passage two. X-axis: log
fluorescence intensity; y-axis: relative cell numbers.
The reactivities of specific and control Abs are shown
by open and closed histograms, respectively. (B)
Northern and (C and D) Western blot analyses.
Third passage bulk microvascular ECs were flow
sorted into podoplanin /CD31 /CD45  BEC and
podoplanin /CD31 /CD45  LEC populations. Af-
ter two further passages cells were harvested and total
cellular RNA and protein were isolated. (B) RNA transfers were sequentially hybridized with 32P-labeled probes derived from the cDNA of podoplanin,
Flt-4, LYVE-1, CD31, and VEGF-C. To ensure equal loading and transfer of RNA, membranes were finally hybridized with an actin probe. Positions
of standards are shown on the right in kb. (C and D) Equal amounts of LEC- and BEC-derived proteins were blotted (D, left panel), membranes were
probed with Abs against podoplanin, KDR, Flt-1, CD31, Tie-1, Tie-2 (C), or Flt-4 (D, right panel), and Ab reactivity was revealed by chemolumines-
cence. Positions of molecular weight markers are shown in kD.802 Phenotype and Function of Lymphatic and Blood Microvascular Endothelial Cells
1 and Tie 2 were expressed at similar levels by BECs and
LECs (Fig. 3, B and C).
Lymphatic ECs Form Continuous Homotypic Cell Junc-
tions. When grown to confluence, ECs of both types se-
quester CD31 and VE-cadherin (Fig. 5, A–D),  - and
 -catenin, and pp120cas (data not shown) into sites of cell
contacts. However, the marginal cell areas occupied by
junctional contacts strikingly differed between LECs and
BECs. Cell junctions between LECs were essentially linear,
well demarcated, and equipped with a continuous but thin
seam of VE-cadherin and CD31 (Fig. 5, A and C). In con-
trast, junctions formed by BECs were ruffled, often in-
dented, and characterized by a broad overlap of the CD31-
and VE-cadherin-bearing cell membranes (Fig. 5, B and
D). By electron microscopy, junctional areas of LECs were
equipped with adherens junctions (Fig. 5 E), gap junctions
(Fig. 5 I), and tight junctions (Fig. 5, E–H). The latter pre-
sumably account for the virtual impermeability of LEC
monolayers for exogenous chemokines, as probed with
CCL19 (see below). Expectedly, adherens, gap, and tight
junctions were observed in BECs (Fig. 5, J–L).
Lymphatic and Blood Vessel ECs Form Homotypic Associa-
tions and Vascular Tubes. When cultures containing BECs
Figure 4. In vitro–cultured LECs contain caveolin and caveolae, and
WP bodies. ECs were grown to confluence, fixed, labeled by indirect im-
munofluorescence for caveolin (A), or by a preembedding immunogold
protocol for podoplanin (B). ECs express uniformly caveolin in a granular
pattern (A) that corresponds in LECs to typical endothelial caveolae by
electron microscopy (B). (C and D) Electron microscopy also reveals WP
bodies in podoplanin-expressing LECs. Original magnification in A:
 700; B:  12.000; C and D:  45.000.
Figure 5. LECs form continu-
ous homotypic cell junctions.
(A–D) Cell contacts formed by
LECs and those by BECs differ
in the extent of junctional pro-
tein recruitment. Confluent
LECs (A and C) and BECs (B
and D) were fixed, and stained
with anti-CD31 (A and B) or
anti–VE-cadherin (C and D).
LECs display a thin rim of CD31
and VE-cadherin in their junc-
tional areas while BECs form
ruffled, indented homotypic
junctions with a broad overlap of
the VE-cadherin- and CD31-
bearing cell membranes. (E-I)
Podoplanin  LECs were identi-
fied by 10 nm immunogold la-
beling. LECs form typical junc-
tional complexes consisting of
adherent junctions (E, double-
headed arrow) and tight junc-
tions (arrowheads in E–H). (I)
Occasionally, gap junctions were
observed. Similar junctional
structures were also found on
cultured, immunogold-negative
BECs (J–L). Asterisk in L indi-
cates a Weibel-Palade body, gap
junctions are marked (GJ). Orig-
inal magnification in A–D:
 700; E, G, I, K, and L:
 75.000; F and J:  40.000; H:
 120.000.803 Kriehuber et al.
and LECs were grown to confluence and replated for 12 h,
islands of LECs formed that were surrounded by BECs
(Fig. 2 C). EC bilayer formation occurred, when the cul-
ture was prolonged for 3 d after the cells had reached con-
fluence. These consisted of plastic-adherent podoplanin /
CD31  BECs and podoplanin /CD31  LECs on top (Fig.
6). In contrast, bilayer formation was never observed in
monotypic cultures of FACS®-sorted LECs and BECs (Fig.
2, A and B).
Does this imply that LECs and BECs are capable of cell
lineage–restricted cell recognition? To address this further,
fluorescent dye–labeled BECs and LECs were subjected to
tube-forming assays on Matrigel. Separately grown BECs
and LECs formed tube-like structures (Fig. 7, A–D). LEC
tubes were thin and rather uniform in diameter (Fig. 7, C
and D), while BEC tubes appeared ragged with prominent
nuclei (Fig. 7, A and B). Optical cross-sectioning of these
EC structures by confocal microscopy revealed occasional
lumen formation (not shown), as also documented by oth-
ers previously (16). Thus, the EC cords formed on Matrigel
are designated “tubes” in this study. When isolated BECs
and LECs were labeled with red and green fluorescent
dyes, respectively, mixed in a 1:1 ratio, and then cultured
on Matrigel, tubes formed that consisted of one EC type
only (Fig. 7, F–G). However, BEC tubes were closely asso-
ciated with LEC tubes (Fig. 7 H).
Lymphatic and Blood Vessel ECs Produce Distinct Chemoat-
traction Signals. Confluent LECs and BECs were stimulated
with TNF  or IL-1  or left nonstimulated. Chemokine
production was assessed by ELISA. Secondary lymphoid
tissue chemokine (SLC)/CCL21 was secreted by nonstim-
ulated and, to a lesser extent, by cytokine-activated LECs
but not by BECs or by other cell types (keratinocytes, fi-
broblasts, large blood vessel ECs) either in their resting or
cytokine (TNF , IL-1 )-activated state (Fig. 8 A). None
of the above cell types released macrophage inflammatory
protein (MIP)-3 /CCL19 whether activated or not (data
not shown). In contrast to the LEC-restricted production
of CCL21, LECs as well as BECs secreted MIP-3 /CCL20
(Fig. 7 B) and monocyte chemotactic protein (MCP-1)/CCL2
(data not shown) upon stimulation with IL-1  and TNF.
To investigate directional chemokine secretion, LECs
were grown to confluence on 0.4- m poresize Transwell™
filters inserted into 24-well tissue culture plates. Then, the
culture medium above and below the membrane-bound
EC monolayers was replaced by TNF - or IL-1  supple-
mented or by nonsupplemented medium, and the amount
of chemokines secreted into the apical and into the basolat-
eral direction was measured after 24 h. To control for
chemokine leakage through the LEC monolayer, CCL19,
which is not secreted by ECs, was added into the upper
compartment and the amount of CCL19 recovered in the
upper and the lower compartment was measured. After
24 h, only 10% of totally recovered CCL19 was in the
lower compartment. Thus, LECs formed a tight barrier that
cannot be easily penetrated even by small molecules like
chemokines (Fig. 8 D). As shown in Fig. 8 C, the vast ma-
jority of CCL20 was secreted in an apical/luminal direction.
Figure 6. BECs and LECs
form separate homotypic layers
in mixed EC cultures. Mixed
BECs and LECs were allowed to
reach confluence and then were
cultured for four additional days.
(A–D) Cells were fixed and
stained with anti-podoplanin Abs
(FITC) and anti-CD31
(TRITC). In the double expo-
sure shown in A, podoplanin /
CD31  ECs (yellow) appear to
cover the monolayer of
podoplanin /CD31  ECs (red).
In B–D, vertical optical section-
ing by confocal microscopy di-
rectly shows that podoplanin /
CD31 /LECs (green; C and D)
are positioned on top of podo-
planin CD31  BECs (red; B
and D). The blue line indicates
the position of the culture dish.
In E, EC bilayers were fixed and
processed for anti-podoplanin
immunogold labeling and verti-
cal sections were analyzed by
electron microscopy. LECs as
identified by their intense label-
ing with 10-nm gold particles are
found on top of nonlabeled
BECs. Original magnification in
A–D:  1,000; E:  40.000.804 Phenotype and Function of Lymphatic and Blood Microvascular Endothelial Cells
In fact, 90% of secreted CCL20 and CCL2 were detected in
the upper chamber (Fig. 8 C). In contrast, more than one
third of SLC/CCL21 was secreted basolaterally (Fig. 8 C).
It is of note that this secretion pattern was not changed by
EC stimulation with proinflammatory cytokines (Fig. 8 C).
Discussion
EC biology and pathology owe their recent explosive
growth, in part, to methods for cell isolation and propaga-
tion. Major advances in these fields, e.g., the identifica-
tion of EC growth factors, chemokines and their recep-
tors, the molecular understanding of how ECs interact
with leukocytes and neoplastic cells, and others (17–20),
were made by using cultured BECs as the research sub-
strate. Due to the lack of specific marker molecules, the
lymphatic EC system has received much less attention and
the molecular mechanisms regulating lymphatic EC and
vessel function have remained largely elusive. This situa-
tion may have also led to misconceptions about microvas-
Figure 7. Lymph and blood ECs
form independent capillary tubes that
wind around each other. Flow-sorted
primary BECs or LECs were ex-
panded through six passages, har-
vested, and labeled with cell-permeant
dyes emitting red and green fluores-
cence, respectively. Labeled BECs (A
and B; red), LECs (C and D; green),
or BECs and LECs mixed in a 1:1 ra-
tio (E–H) were seeded onto Matrigel,
cultured in EGF- and hydrocortisone-
deficient medium for 24 h, fixed, and
analyzed by confocal microscopy. A,
C, and E are phase contrast images
corresponding to the fluorescence im-
ages B (red), D (green), and F–H
(green, red), respectively. F and G
show the single red and single green
fluorescence signals of the double ex-
posure in H. (F and G) In mixed cul-
tures, BECs and LECs form tubes that
are built up by one EC subtype only.
(H) Homotypic BEC and LEC tubes
are closely juxtaposed in a double heli-
cal pattern. Original magnification in
A–G:  100; H:  400.
Figure 8. Chemokine secretion of isolated LECs and BECs. (A and B) LECs, but
not BECs, secrete SLC/CCL21, but both EC types produce MIP-3 /CCL20 upon
activation. EC subsets grown to confluence were exposed to EGF- and hydrocorti-
sone-deficient medium (non-stim.) or to the same medium supplemented with
TNF  or IL-1 . 24 h supernatants were analyzed by CCL21- (A) and CCL20-spe-
cific ELISAs (B). The concentrations of chemokines produced by BECs (hatched
bars) and LECs (black bars) are shown (mean values ( SD) obtained in two inde-
pendent experiments). (C) LECs secrete CCL21 but not CCL20 basolaterally. LECs
grown to confluence on 0.4- m poresize TranswellTM filters, were nonstimulated
(non-stim.) or stimulated with TNF - or IL-1  for 24 h. CCL21 (black bars) and
CCL20 (hatched bars) secreted into the upper (apical) and the lower (basolateral)
chamber of the Transwells™ were measured. The percentage of chemokine recov-
ered from the lower chamber relative to the total amount of secreted chemokine
(i.e., secreted into the upper and lower chamber) is shown. Mean values ( SD) ob-
tained from triplicate cultures; n.d.; not done. (D) LEC monolayers form a tight bar-
rier for exogenous CCL19 used as a tracer. To control for leakage of chemokines
through the LEC monolayer, MIP-3 /CCL19 was added to the upper chamber.
Data are given as the percentage of the amount of chemokine recovered from the
lower chamber relative to the amount of chemokine retrieved from the upper and
lower chamber. Approximately 80% of initially added CCL19 was recovered after
24 h. Mean values ( SD) obtained from triplicate cultures.805 Kriehuber et al.
cular BEC gene expression and function since bona fide
BECs may be “contaminated” by LECs. Until the not so
distant past, lymphatic vessels were defined by the absence
of erythrocytes from their lumen, and LECs, compared
with BECs, by their less elaborate cell junctions and base-
ment membranes as well as their low level expression of
CD34 and vWF (6, 7). Recently, two glycoproteins were
discovered that are selectively expressed in LECs, but not
in BECs. These are the transmembrane protein podopla-
nin, originally found in glomerular podocytes (21), and a
CD44-related hyaluronic acid receptor designated LYVE-1
(10). The expression pattern of these markers is conserved
in rodents, as the podoplanin ortholog E11/T1   in rat
(22, 23), and the LYVE-1 ortholog in mice (24) are ex-
pressed by lymphatic but not blood ECs. Human
podoplanin was localized on the LEC surface by immuno-
electron microscopy, and found to resist protease treat-
ment used to dissociate cutaneous microvascular cells
(reference 4; this study). These properties qualified podopla-
nin as useful marker for the separation of dermal LECs
and BECs by FACS®.
In the past, several attempts have been made to obtain
pure populations of bona fide LECs, for example by isolat-
ing cells from lymphatic vascular tumors (25, 26). Again,
due to the lack of specific markers, the histogenetic origin
of these expanded ECs could not be defined, or the isolated
neoplastic ECs did not maintain a stable phenotype in cul-
ture. The triple fluorescence FACS® strategy used in this
study allows for the first time the establishment and stable
propagation of nontransformed, pure LECs and BECs.
LECs were defined by the expression of podoplanin and
CD34, and lack of CD45. Vice versa, BECs expressed
CD34, but were devoid of podoplanin and CD45. These
immunophenotypes directly relate to those of LECs and
BECs in vivo. The podoplanin  and podoplanin  pheno-
type of LECs and BECs, respectively, were equally con-
served after direct isolation of ECs (Materials and Methods,
approach A) and following EC subset purification from
bulk EC cultures (Materials and Methods, approach B).
In the latter expansion cultures, compact islands of
podoplanin  ECs were always surrounded by a lawn
of podoplanin  ECs, and there was no apparent selection
of one over the other subset. Similar to podoplanin,
LYVE-1 remained stably expressed in cultured LECs for up
to seven passages and was not induced in BECs. Vice versa,
the antigen defined by mAb Pal-E was expressed in BECs
but not in LECs. Common EC markers, such as CD31,
VE-cadherin, UEA I reactivity, caveolin, vWF, and corre-
sponding WP bodies, were observed in both LECs and
BECs, though at somewhat different quantities. Thus, pro-
teins that are exclusively expressed, or shared, by LECs or
BECs in vivo remained unchanged during in vitro propa-
gation of the isolated EC populations. Collectively, our
studies on ex vivo isolated and in vitro propagated EC sub-
sets strongly support that LECs and BECs represent two
distinct and stable microvascular EC lineages.
Recently, VEGF-C was established as a lymphatic ves-
sel–specific growth factor as evidenced by dermal lymphan-
gioma-like vessel proliferation in mice that overexpress
VEGF-C in the epidermis (27). Moreover, the induced ex-
pression of VEGF-C and -D in tumor cells caused massive
intra-/peritumoral growth of lymphatic vessels and en-
hanced lymph node metastasis in mice (28–31). Here we
show that VEGF-C mRNA and protein are produced by
BECs, but not, or in minute quantities only, by LECs.
Conversely, the receptor for VEGF-C, Flt-4, was almost
exclusively expressed by LECs, rather than by BECs (Fig.
3, B and D). LECs produced three major Flt-4 isoforms,
corresponding by MW to the mature form ( 195 kD) of
Flt-4 (15; Fig. 3 D), a nonglycosylated backbone ( 140
kD), and the major precursor ( 175 kD). A  125 kD
cleaved/processed COOH-terminal fragment of Flt-4 (15)
was also detected on LECs, and in even higher levels on
BECs (Fig. 3 D, and data not shown). Evidence was pro-
vided in this study, by different independent methods, that
Flt-4 is expressed, though at low levels, by dermal BECs.
The potential of BECs to express Flt-4 is further docu-
mented by pronounced Flt-4 expression on endothelia of
tumor-associated blood vessels (12, 14). Furthermore, the
weak Flt-4 expression of normal BECs (12) may have es-
caped detection by in situ labeling techniques used in pre-
vious studies. The other VEGF receptors, KDR and Flt-1,
and the angiopoietin receptors Tie 1 and Tie 2 were de-
tected in LECs and BECs at similar levels. These results
raise the possibility that BECs use the VEGF-C-Flt-4 re-
ceptor system for unidirectional, interlineage communica-
tion with LECs. In vivo, the regeneration of lymphatics
follows that of blood vessels with a significant delay,
thought the reason for this has remained unexplained (2).
Our data offer the appealing explanation that the blood
vasculature has to reestablish before it directly induces pro-
liferation of LECs and sprouting of new lymph vessels via
the secretion of VEGF-C.
Do BECs and LECs form homotypic or also heterotypic
cell contacts? Individually grown LECs and BECs formed
conventional EC monolayers when grown to confluence.
In mixed cultures that contained both EC types, LECs and
BECs could not be distinguished by morphology, thus
pretending their belonging to a single cell lineage. How-
ever, anti-podoplanin immunostaining revealed that LECs
formed islands of homotypic cell aggregates. This homo-
typic association was even more evident when mixed cul-
tures were grown to confluence, and EC bilayers formed
that consisted of a lower layer of BECs and of an upper
layer of LECs. This indicates specific mechanisms of homo-
typic recognition and formation of cell contacts, and pre-
sumably also different strength of cell-substrate adhesion.
Also, signals elaborated by either cell type do not suffice to
arrest growth of the other cell type.
Homotypic cell association was observed also when
mixed EC populations were subjected to vascular “tube-
formation” assays in Matrigel. LECs and BECs formed cap-
illary “tubes” equally well when cultured separately. When
fluorescence-tagged LECs and BECs were mixed in equal
numbers and cocultured in Matrigel, continuous, strictly
homotypic tubes emerged that were invariably closely asso-806 Phenotype and Function of Lymphatic and Blood Microvascular Endothelial Cells
ciated with each other, occasionally resembling helical
doublets. This topographic behavior strikingly resembles
the in vivo association of lymphatic and blood vessels in
many tissues (1–3). A plausible explanation for this phe-
nomenon could be that VEGF-C released from BECs
“cross-talks” with its receptor Flt-4 that is primarily ex-
pressed on LECs.
While the molecular basis of this remarkable selectivity
in cell–cell interaction remains to be established, our results
show that cell contacts between LECs and those between
BECs strikingly differ in the amount of junctional protein
recruitment, and in the degree to which adjacent cell
membranes were juxtaposed. LECs expressed less VE-cad-
herin, CD31, and catenins than BECs at junctional sites
and formed rather narrow contact areas with neighboring
cells. Nevertheless, LECs formed organized and close cell
contacts that involved adherens, gap, and, even, tight junc-
tions and were only poorly penetrated by exogenous solu-
ble proteins. These elaborate and complex cellular inter-
actions and junctions suggest a more stringent barrier
function of LECs in lymphatic vessels than previously an-
ticipated. Similar to BECs, LECs contain typical endothe-
lial caveolae that mediate transcytotic transport across the
endothelial barrier.
Lymphatic capillaries direct migratory APCs, i.e., den-
dritic cells (DCs), from the tissues toward the regional
lymph nodes (32). It is still undecided whether LECs ac-
tively recruit tissue DCs into the lymphatic channels or
merely provide a structural scaffold for continuous lymph
fluid. The CC chemokine receptor 7 (CCR7) ligands
SLC/CCL21 and MIP-3 /CCL19 were recently associ-
ated with the regulation of DC emigration from the tissues
(33–36). Here we show that SLC/CCL21 is expressed in
an activation-independent fashion by isolated LECs, but
not by BECs and many other cell types. Moreover,  30%
of this chemokine was secreted at the basolateral aspect of
LECs while the inducible chemokine MIP-3 /CCL20
was secreted apically/luminally by BECs and LECs. The
second known CCR7 ligand, CCL19, although found as-
sociated with afferent lymphatics by immunohistochemis-
try (37), was not secreted in significant amounts by either
EC type whether stimulated or not. Thus, basolaterally/
abluminally secreted SLC/CCL21 is a prime candidate for
the recruitment of CCR7-expressing mature DCs from
the interstitial spaces toward lymph vessels. LEC-derived
SLC can also be of central importance for the dissemina-
tion of certain cancers. Melanoma and breast cancer cells,
unlike their nontransformed counterparts, express func-
tional CCR7 (38). Presumably, LECs actively control im-
mune and tumor cell trafficking, using the similar ligand-
receptor systems.
Mice with a deletion in the Scya21a gene (plt, paucity of
lymph node T cell mice) fail to express CCL21 in lym-
phoid organs but express the Scya21b gene product SLC-
Leu/CC21b in lymphatic ECs of nonlymphoid tissues (39).
plt mice, in striking contrast to CCR7 /  mice, show nor-
mal delayed-type T cell responses (36, 40). It thus follows
that LEC-derived rather than lymph node–expressed SLC
is indispensable for proper DC homing to lymph nodes
and, consecutively, T cell priming.
The fraction of SLC/CCL21 and MIP-3 /CCL20 that
LECs secrete into the apical direction and thus presumably
into the lumen of lymphatic capillaries will drain into re-
gional nodes. As intradermally injected chemokines can be
presented by ECs of high endothelial venules in lymph
nodes (41), it is conceivable that LEC-derived CCL20 and
CCL21 assist the recruitment of blood-borne CCR6  and
CCR7  leukocytes into T cell zones of draining nodes.
This would assign to LECs a novel immunoregulatory
function for assuring optimal immune surveillance.
Taken together, stable EC subset-restricted gene expres-
sion and polarized secretion of function-related chemo-
kines demonstrate that LECs and BECs belong to two dif-
ferent EC lineages. This is in agreement with the EC
subtype-restricted importance of certain homeobox gene
products, e.g., Prox-1, for the development of the lym-
phatic but not the blood vascular system (42). The avail-
ability of microvascular LECs will now allow the resolution
of their genetic and functional programs, will help to un-
cover their contribution to the molecular pathogenesis of
fatal conditions, such as cancer dissemination or transplant
rejection, and, hopefully, will provide clues for the design
of novel therapeutic strategies.
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